Ophthalmic Drug Research Platform

◆ Platform Overview

图层 1`.jpg

◆ Team Introduction

LEWWIN PHARM possesses a relatively independent professional team dedicated to non-clinical evaluation research of ophthalmic drugs, comprising nearly 100 members, including over 10 high-level experts, with over 40% holding Ph.D., M.S or M.V.M degrees. It jointly established the Guangdong Engineering Technology Research Center of Ophthalmic Drug Creation and Evaluation, as well as the National Key Laboratory for the Prevention and Treatment of Ophthalmic Diseases (Research Center for Non-Clinical Evaluation of Ophthalmic Drugs), holding a leading position in China.

图层 3.png

◆ Route of Administration

● Topical Administration to the Eyes：

   Topical Ophthalmic Use (eye drops, eye ointments, ophthalmic gels)

   Periocular Injection (subconjunctival, sub-Tenon’s, retrobulbar)

   Intraocular Injection (anterior chamber, intravitreal)

   Fundus Administration (subretinal)

● Systemic Administration: oral, intramuscular injection, intravenous injection

● Blood-Ocular Barrier: depends on the lipophilicity of the drug; drugs with high lipophilicity readily permeate the blood-ocular barrier and enter the eye.

组 2.png

◆ Pharmacokinetics

  • Sophisticated eye surgery that isolates the eye into 14 tissues

  • Proven ocular tissue sampling, homogenization, and testing techniques

  • More than 30 PK studies on ophthalmic drugs have been completed

11页.jpg

◆ Pharmacology Model

●  Models of ophthalmic diseases available

1.2·.png

◆ Instruments and Equipment

1.3`.png